Histone deacetylases (HDACs) form a family of enzymes, which have fundamental roles in the epigenetic regulation of gene expression and contribute to the growth, differentiation, and apoptosis of cancer cells. In this study, we further investigated the biological function of HDAC5 in cancer cells. We found HDAC5 is associated with actively replicating pericentric heterochromatin during late S phase. We demonstrated that specific depletion of HDAC5 by RNA interference resulted in profound changes in the heterochromatin structure and slowed down ongoing replication forks. This defect in heterochromatin maintenance and assembly are sensed by DNA damage checkpoint pathways, which triggered cancer cells to autophagy and apoptosis, and arrested their growth both in vitro and in vivo. Finally, we also demonstrated that HDAC5 depletion led to enhanced sensitivity of DNA to DNAdamaging agents, suggesting that heterochromatin de-condensation induced by histone HDAC5 silencing may enhance the efficacy of cytotoxic agents that act by targeting DNA in vitro. Together, these results highlighted for the first time an unrecognized link between HDAC5 and the maintenance/assembly of heterochromatin structure, and demonstrated that its specific inhibition might contribute to increase the efficacy of DNA alteration-based cancer therapies in clinic.
1
Several compounds were identified as broad-spectrum inhibitors of class-I and -II HDAC (HDACi). 2 These HDACis can cause cell-cycle arrest, activation of programmed cell death (apoptosis/autophagy), or inhibition of angiogenesis. Based on their potent anticancer effects in vitro, several HDACis are currently being investigated in clinical trials in cancer patients, both as single agents and in combination with other drugs. The FDA (Food and Drug Administration) approval of SAHA (suberoylanilide hydroxamic acid; Zolinza) for treatment of cutaneous T-cell lymphoma 3 validates the concept of HDAC inhibition to treat cancer.
Generally, HDACis are well tolerated when compared with most of the currently used antitumor treatments. However, some side effects have been reported. So, by targeting the most relevant HDAC members, it may be possible to improve efficacy by removing undesirable toxicities. Preclinical investigations by targeted knockdown of individual HDAC members demonstrated the roles of class IIa HDACs in tumorigenesis. Indeed, we and others have demonstrated that silencing of HDAC4 inhibited cancer cell proliferation in vitro and arrested tumor growth in vivo through epigenetic regulation of p21 WAF1/Cip1 gene expression. 4, 5 Recently, Zhu et al. 6 also demonstrated HDAC7 is a crucial player in cancer cell proliferation. Together, these findings would suggest that inhibition of class IIa HDACs might be a sufficient strategy to treat cancer. However, the contribution of HDAC5 to tumor progression is largely ignored and needs to be further characterized to determine whether class IIa HDAC members are the most relevant targets in cancer therapy. The human HDAC5 gene is located on chromosome 17q21, a region which is characterized by losses of chromosomal material in different cancers. 7 Moreover, HDAC5 expression is frequently reduced in cancer such as colon cancer and acute myeloid leukemia, [8] [9] [10] and is associated with poor clinical outcome of lung cancer patients. 11 In contrary, an upregulation of HDAC5 has been observed in high-risk medulloblastoma and its expression is associated with poor survival. 12 Like for many HDACs, HDAC5 is then aberrantly expressed in tumors, suggesting that this HDAC may have a role in tumor progression.
Here, we investigated the function of HDAC5 in cancer cells. We found that its sub-nuclear localization changed during S phase progression, with HDAC5 colocalizing with actively replicating heterochromatic regions during late S phase. We demonstrated that its specific depletion by RNA interference (RNAi) induced a defect in pericentric heterochromatin assembly and slowed down an ongoing replication fork, which consequently induced DNA-damage checkpoint pathways, which leads to cell-cycle blocking, inhibition of cell proliferation, induction of apoptosis as well as autophagy, and, consequently, decreased tumor growth in vivo. Altogether, these findings implicate HDAC5 in the maintenance/assembly of pericentric heterochromatin structure and demonstrate that class IIa HDAC5 can represent a potential target for anticancer therapies.
Results
HDAC5 localizes to pericentromeric heterochromatin primarily during late S phase. To explore the function of HDAC5, we first examined its localization in HeLa cells. Confocal microscopy showed that approximately 85% of asynchronous cells showed a nuclear localization, with more intense foci around the nucleolus ( Figure 1A ). This localization was observed in different cell types, including MCF-7, MDA-MB-231, endothelial cells, and fibroblasts (data not shown). Transfection with two different efficient HDAC5 small interfering RNA (siRNA) correlated with loss of nuclear HDAC5 foci, excluding a non-specific staining (Supplementary Figures S1A, and S1B-S2). This localization was also confirmed with a second anti-HDAC5 antibody (Supplementary Figure S1C) . To further characterize the intra-nuclear localization of HDAC5, we performed electron microscopy. Endogenous HDAC5 was detected as individual foci in the nucleus and the clusters showed a preferential colocalization of HDAC5 with pericentric (pericentromeric) heterochromatin ( Figure 1B and Supplementary Figure S3 ). As fluorescence-activated cell sorting (FACS) analysis (see Figure 2a) revealed that an asynchronous population of HeLa cells is composed of 65-70% of cells in G 1 , 20-25% of cells in S, and 5-10% of cells in G 2 /M phase, we hypothesized that HDAC5 could target pericentric heterochromatin during different phases of the cell cycle. First, we monitored the localization and expression of HDAC5 during S phase. In early S phase, HDAC5 shows a diffuse nuclear staining, but in late S phase, the patterns were strikingly different, with HDAC5 now colocalizing with proliferating cell nuclear antigen (PCNA) to punctuate foci that are characteristic of late-replicating pericentric heterochromatin ( Figure 1C) . A colocalization between HDAC5 and heterochromatin protein 1 (HP-1), a heterochromatin marker, in late S phase confirmed that HDAC5 is localized to heterochromatic regions ( Figure 1D ). The re-entry into S phase was monitored by both FACS (see Figure 1C ) and western blotting against cyclin E and phospho-histone H3 on Ser10, two markers of S phase progression, 13, 14 a period during which the global level of HDAC5 did not change ( Figure 1E ). During mitosis, HDAC5 was not detectable with mitotic chromosome. However, we observed that HDAC5 also associated with heterochromatin in the G 1 phase (Supplementary Figure S4) . Bearing in mind the importance of HDAC for chromatin condensation, we assessed the impact of HDAC5 depletion on the organization of pericentric heterochromatin by electron microscopy. Electron micrographs of GL3 siRNA/mock-transfected cells revealed dense nucleoli and a condensed pattern of heterochromatin. By contrast, HDAC5-depleted cells showed a reduced number of dense heterochromatin clusters at the periphery of the nucleolus, demonstrating failure of appropriate assembly/maintenance of chromatin structure at pericentric heterochromatin ( Figure 1F ). To determine whether HDAC5 depletion exerted a more global influence on chromatin organization, we performed a MNaseI (micrococcal nuclease 1) assay. No defects in wrapping of DNA by the histone octamer were observed in the absence of HDAC5 ( Figure 1G ), suggesting that HDAC5 did not have a role in the assembly/maintenance of nucleosome organization.
HDAC5 depletion affects DNA replication efficiency and cell-cycle progression. Because heterochromatin assembly and DNA replication are tightly coupled, we examined the consequences of HDAC5 depletion on DNA replication and S phase progression. To identify the effect of HDAC5 depletion on global S phase, asynchronous cells were transfected with an HDAC5 siRNA for 24, 48, and 72 h, and then pulsed with 5-bromo-2 0 -deoxyuridine (BrdU) before FACS analysis. After 24 h, the number of replicating cells in HDAC5-depleted cells was 28.8% lower compared with mock-transfected cells, and most of the cells were blocked in the G 1 phase (Figures 2a and b) . Forty-eight hours after transfection, the percentage of replicating cells was significantly higher in HDAC5-depleted cells (28.23%) compared with control conditions (Figures 2c and d) . After 72 h, no significant changes were observed (Figures 2e  and f) . These data show that HDAC5 siRNA-transfected cells are first blocked in G 1 /S and then re-enter S phase later despite still efficient HDAC5 inhibition (Figure 2g ). However, this reversible cell-cycle blocking was not observed in MCF-7 cells (data not shown).
To further investigate whether HDAC5 depletion altered cell-cycle progression, HDAC5-depleted cells were treated with the mitotic inhibitor nocodazole 24 h before harvesting (E) Levels of HDAC5 protein during S phase progression. Whole-cell lysates were prepared from asynchronous, early S, mid-S, or late S phase, and the lysates were analyzed by western blotting using anti-HDAC5, anti-cyclin E, and anti-phosphoSer10 H3 antibodies. HSC70 was used as a loading control. (F) HDAC5 depletion alters chromatin structure. Electron microscopic analysis of MCF-7 cells transfected with either a GL3 siRNA or with an HDAC5 siRNA for 24 h. GL3 siRNA-transfected cells showed dense nucleoli and a condensed pattern of heterochromatin (black arrows). By contrast, HDAC5-depleted cells showed an even dispersion of the chromatin. FC, fibrillar center; D, dense fibrillar components; G, granular components (bar: 0.5 mm).(G) Nuclei extracted from MCF-7 cells transfected with No siRNA, GL3 siRNA, or with HDAC5 siRNA for 48 h were digested with increasing concentrations of MNase and analyzed by gel electrophoresis control cells, suggesting that cells seem to adapt or recover from HDAC5 loss, thus ensuring normal cell-cycle progression ( Figure 3 ).
HDAC5
depletion inhibits replication fork progression. The inability to remove histones in front of the replication fork or to load nucleosomes behind the fork can impede replication progression. To test whether HDAC5 depletion affected replication fork progression, we performed DNA fiber assay (Figure 4a) . A comparison of DNA fibers from control-and HDAC5 siRNA-transfected cells revealed a striking difference in the overall length of their replication tracks ( Figure 4b ) and stalled replication fork were commonly observed when HDAC5 is depleted (Supplementary Figure S5 ). When distribution of fibers length was quantified and plotted, the entire distribution of fiber length in HDAC5-depleted cells shifted leftward to shorter fibers (Figure 4c) . Quantification of the doubly labeled fibers indicated that the average rate of fork progression in HDAC5-depleted cells was 1.26-fold slower than in control cells, suggesting that replication forks progressed at a slower rate in the absence of HDAC5 (Figure 4d) .
DNA replication is a multi-step process, which first requires loading of DNA replication licensing factors. The chromatin association of ORC (origin recognition complex) and MCM (mini-chromosome maintenance protein) subunits, and PCNA, which are DNA replication licensing factors-was not altered in the absence of HDAC5 (Figure 4e ), suggesting that replication factors were assembled normally and the replication defect occurred downstream from replication factor recruitment. Analysis of the activities of lamin B2, an early replication origin, and, Ors8, a late replication origin, demonstrated that HDAC5 depletion affected the firing of origins. Indeed, firing from both origins was reduced by approximately 40% at 24 h after transfection, whereas it was significantly increased after 48 h of transfection (Figures 4f and g ).
HDAC5 depletion induces DNA damages and activates DNA-damage checkpoint pathways. Changes in heterochromatin structure alter fork progression. DNA doublestrand breaks (DSBs) arise frequently as a consequence of replication fork stalling. One of the first molecules to appear following DSB formation is the phosphorylated form of H2AX histone variant on Serine 139 (g-H2AX). Inhibition of HDAC5 expression led to a significant increase in g-H2AX as early as 24 h after transfection as shown by western blotting and single-cell electrophoresis assay (Figures 5a and b) , suggesting that HDAC5 depletion leads to DNA damages. A co-staining between g-H2AX and BrdU revealed that these DNA damages occur at replication sites mainly in mid-to late S phase ( Figure 5c and Supplementary Figure S6 ). DNA damages during S phase activate the intra-S phase checkpoint and involve transducer kinases such as checkpoint kinase 1 (Chk1) and/or Chk2. 15, 16 The active form of Chk1 but not Chk2 was detected in HDAC5-depleted cells. The level of p53, a downstream target of Chk1, is slightly increased 24 h after HDAC5 depletion, but it declined thereafter, and reached the basal level after 32 h. In HDAC5-depleted cells, the p53 target gene p21 WAF1/Cip1 also showed a similar rise and fall, although it faded off more slowly. Similarly, upregulation of p27 kip1 and p16INK4A, two other cyclin-dependent kinase (CDK) inhibitors (CDKi), was transient and not sustained over time. As attempted, these CDKis inhibit the phosphorylation of retinoblastoma protein (pRb), thereby preventing E2F1 from transcribing genes that are required for cell-cycle progression such as cyclin A or E2F1 itself (Figure 5d ). However, induction of these CDKis and accumulation of hypo-phosphorylated pRB were not maintained after 72 or 96 h (Figure 5e ), showing that HDAC5 depletion caused a transient induction of CDKis that decline slightly at basal level later.
To see whether induction of both p53 and p21 WAF1/Cip1 was similar in other cell types, we explored the consequences of HDAC5 contributes to tumor progression P Peixoto et al HDAC5 depletion in MCF-7 cells, which also harbors wild-type p53 and pRb genes. In those cells, HDAC5 depletion also induced activation of the p53-p21 WAF1/Cip1 and pRb pathways, but the induction was more persistent compared with HeLa cells (Figure 5f ).
HDAC5 depletion induced both apoptosis and autophagy. HDAC5 depletion induced a DNA-damage response, which engages both the p53-p21 WAF1/Cip1 and the p16INK4A-pRb pathways. These pathways can establish and maintain the growth arrest that is typical Figure S8) .
As autophagy and apoptosis can share common components and inhibitory/activating signaling pathways, we next determined whether HDAC5 depletion could also induce autophagy by analyzing the level of LC3, an autophagosomal marker. LC3-II levels (compared with b-actin loading controls) increased in both HeLa and MCF-7 cells depleted for HDAC5 (Figures 6c and d, bottom panels) , suggesting concomitant induction of apoptosis and autophagy. This amount of LC3-II further accumulates in the presence of a lysosomal inhibitor, indicating enhancement of the autophagic flux (Supplementary Figure S9A ). To further confirm activation of autophagy, both HeLa and MCF-7 cells were stained with an LC3 antibody MCF-7 HeLa and presence of autophagic vacuoles was analyzed by confocal microscopy. Figures 6e and f showed the presence of autophagic vacuoles in both HeLa and MCF-7 depleted for HDAC5. This formation/accumulation of autophagic vacuoles was confirmed by electron microscopy (Supplementary Figure S9B) .
HDAC5 depletion globally reduces cancer cell proliferation, survival, and inhibits tumor growth in vivo. Because HDAC5 depletion affects cell-cycle progression, and induces both apoptosis and autophagy, we assessed the effect of HDAC5 depletion on the global cancer cell proliferation, survival, and tumor growth. In vitro, HDAC5 depletion significantly decreased proliferation (Figures 7a and b) as well as survival (Figures 7c and d) of both HeLa and MCF-7 cells. To examine the effect of HDAC5 depletion on tumor cell growth, we used an in vivo model in which cancer cells are engrafted onto embryonated chick chorioallantoic membrane (CAM). Tumors formed from HDAC5-depleted MCF-7 cells (Figures 7e-g ) were smaller than control tumors, demonstrating the relevance of inhibiting HDAC5 in cancer cells in vivo.
depletion increases the efficacy of chemotherapeutic drugs in vitro. It has become increasingly clear that the chromatin compaction present in heterochromatin helps to protect DNA from damaging drugs. 17 As such, knockdown of heterochromatic proteins or induced de-condensation of chromatin sensitizes cells to DNA damages. 18 According to our data, HDAC5 depletion could expose heterochromatic regions to DNA-damaging drugs. Therefore, we examined whether HDAC5 depletion could sensitize cancer cells to chemotherapeutic drugs. MCF-7 or HeLa cells were transfected with a siRNA against HDAC5 for 24 h, and then incubated either with doxorubicin or cisplatin for an additional 24 h. Loss of HDAC5 caused 5-6 times more apoptosis compared with cisplatin or doxorubicin alone in HeLa cells (Figures 8a-c) . Interestingly, the combination of HDAC5 siRNA/doxorubicin or cisplatin produces more cell death than chemotherapeutic drugs associated with trichostatin A (TSA), a broad-spectrum HDACi (Supplementary Figures S10A and S10B) , demonstrating that only inhibition of HDAC5 produces better cytotoxicity than HDACi to potentiate chemotherapeutic drugs.
Using the same schedule, HDAC5 depletion in MCF-7 cells did not potentiate the activity of chemotherapeutic drugs. To test whether this schedule alters the effectiveness of combination treatment, HDAC5-depleted MCF-7 cells were exposed to DNA-damaging drugs 48 h after siRNA transfection for an additional 24 h. A better cytotoxic/apoptotic effect was observed (Figures 8d and e , and Supplementary Figure S10C ) suggesting that appropriate sequencing and scheduling of the combination of HDAC5 silencing with DNA-damaging drugs is required for each cancer cell type.
Discussion
The inheritance and faithful maintenance of chromatin organization is crucial for eukaryotic cells. To orchestrate DNA replication in the context of chromatin, cells have evolved efficient nucleosome dynamics involving assembly pathways and chromatin maturation mechanisms. During replication, modified parental histones are displaced ahead of the replication fork and are randomly distributed between the two daughter strands. Concomitantly, deposition of de novosynthesized histones H3 and H4 provides the full complement of histones that are needed to ensure proper assembly of the duplicated material. During its initial synthesis, histone H4 is acetylated at lysine residues 5 and 12. These residues must be deacetylated to form heterochromatin in late S phase, thus ensuring secure maintenance of the under-acetylated state of heterochromatin. This latter step is promoted through the action of HDAC-containing complexes such as Mi-2/NuRD (nucleosome-remodeling deacetylase complex) and/or the Sin3/HDAC chromatin-modifying complex, 19 which have been shown to contain both HDAC1 and HDAC2, and associate with pericentric heterochromatin during S phase. 20, 21 Whereas some reports pointed to the role of HDAC2 in the rearrangement of the nucleosomes during the formation of heterochromatin in late S phase, 22 as well as the implication for HDAC3 in replication fork progression, 23, 24 we demonstrated that HDAC5 is recruited to heterochromatin regions, probably with members of NuRD/Sin3 chromatin remodeling complexes as well as with other epigenetic regulators such as DNA methyltransferase 1 (DNMT1) or HP-1, 22, [25] [26] [27] [28] to participate in the establishment of the pericentric heterochromatin structure in late S phase. However, the mechanisms of action of HDAC5 in the assembly/ maturation of pericentric heterochromatin remain to be identified.
The chromatin structural defect caused by HDAC5 depletion results in a slow-growth phenotype, with delayed cellcycle progression and activation of multiple checkpoints pathways. We indeed observed: (i) activation of the Chk1-dependent intra-S phase checkpoint, which could survey alterations in chromatin structure, and serves as an efficient mechanism to slow down fork progression in the absence of appropriate chromatin assembly and block initiation of new replication forks in a global manner, consistent with reports showing that origin firing is inhibited during S phase when DNA damage or replication fork stalling activates the intra-Sphase checkpoint kinases; [29] [30] [31] and (ii) activation of a G 1 /S checkpoint pathway, which prevents late-G 1 cells from entering the S period by directly or indirectly inhibiting initiation at the earliest-firing origins, with the consequence that the entire S period is delayed along the cell-cycle axis. 29, 30 In addition to cell-cycle blocking, we also observed activation of autophagy in HDAC5-depleted cells. Numerous studies suggest that autophagy may function in the regulation of cell survival and have a major role in the maintenance of genomic integrity. 32 The precise role of autophagy in response to HDAC5 depletion is not fully understood yet but is thought to be a temporary survival mechanism, which delays apoptosis as inhibition of HDAC5 silencing-induced autophagy unmasks and accelerates apoptosis (data not shown).
Activation of checkpoint pathways and consequently cell-cycle blocking in HDAC5-depleted cells should allow time for the chromatin defects to be resolved. Once repair is accomplished, these checkpoint/repair pathways are usually silenced so that cell-cycle progression is allowed to resume. After an initial attempt to recover or adapt, prolonged HDAC5 inhibition in HeLa cells overwhelms the cells and results in apoptosis, suggesting that either chromatin defects are too severe or recovery/adaptation mechanisms are followed by excessive genome instability, leading to cell death in subsequent cell cycles for a subpopulation of cells. In addition to activation of the apoptotic program, we noted that autophagy is still induced at late time point in the time course of HDAC5 depletion. Despite its initial role as a survival pathway, progressive autophagy can result in cell death if allowed to proceed to completion under persistent stress and therefore, both processes would cooperate to lead to cell death.
The role of HDAC5 in heterochromatin assembly and maturation also has an impact in DNA alteration-based cancer strategies. Consistent with others studies, 34, 35 we reported here that HDAC5 depletion potentiates the effect of chemotherapeutic agents that target DNA by inducing heterochromatin de-condensation, thereby facilitating access of drugs to DNA. Despite a more accessible chromatin in both cell types, we found that a different sequencing and scheduling of the combination of HDAC5 silencing with DNA-damaging drugs is required for each cancer cell types. Why did HDAC5-depleted MCF-7 cells show a delayed death response to DNA-damaging drugs compared with HeLa cells? In MCF-7 cells, several factors such as caspase-3 deficiency, levels and activity of the Bax (Bcl-2-associated X)/Bcl-2 (B-cell lymphoma 2) proteins, or activation of phosphoinositide-3-kinase (PI3K)/Akt (protein kinase B) kinases can contribute to refractory to apoptosis induced by DNAdamaging drugs. Autophagy also represents a mechanism of resistance to modalities, which affect DNA. Because induction of autophagy delays apoptosis in the absence of HDAC5 only, we are currently focusing our research to further understand the impact of autophagy in the death response of HDAC5-depleted cells treated with chemotherapeutic agents.
Altogether, our findings revealed that HDAC5 is a regulator of pericentric heterochromatin assembly, and demonstrated that its inhibition alone or in combination with chemotherapeutic agents might represent a promising strategy in cancer therapy.
Materials and Methods
Cell culture, synchronization, and treatment. HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% heatinactivated fetal bovine serum (FBS). MCF-7 cells were maintained in a-Modified Eagle's Medium (aMEM) supplemented with 10% heat-inactivated FBS. Synchronization was achieved by treating cells with 2 mM hydroxyurea (Sigma) and 200 mg/ml nocodazole (Sigma, St. Louis, MO, USA). TSA, cisplatin and doxorubicin were purchased from Sigma.
Antibodies. Anti-FLAG and anti-BrdU (clone BU-33) antibodies were purchased from Sigma. Anti-BrdU (clone BU1/75), anti-ORC1, anti-ORC3, and anti-ORC4 antibodies were from AbDSerotec (Kidlington, UK). Anti-HDAC5, anti-p16INK4A, anti-MCM2, anti-MEK2 (MAPK/ERK kinase 2), anti-ORC2, anti-Chk1, anti-phosphoSer317 Chk1, anti-Chk2, anti-phosphoThr68 Chk2, and anti-caspase-3/7 antibodies were purchased from Cell Signaling (Carlsbad, CA, USA). Anti-HDAC5, anti-histone H2AX, anti-phosphoSer139 histone H2AX and anti-phosphoSer10 histone H3 antibodies were from Millipore (Bedford, MA, USA). Anti-BrdU (clone B44), anti-MCM4, anti-MCM5, anti-MCM6, anti-p27, anti-pRb, anti-cyclin E, and anti-cyclin A antibodies were purchased from BD Biosciences (Erembodegem, Belgium). Anti-p53 antibodies were from Upstate Biotechnology (Lake Placid, NY, USA). Anti-p21
, anti-E2F1, anti-MCM3, anti-Cdc6, anti-PCNA (clone PC10), anti-HP-1, anti-HDAC5, and anti-HSC70 (heatshock cognate 70-kDa protein) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-LC3 antibodies were purchased from Abgent (San Diego, CA, USA).
siRNA transfection. siRNAs were synthesized either by Eurogentec (Liège, Belgium) or Dharmacon (Lafayette, CO, USA). Calcium phosphate-mediated transfections were performed as described previously. 36 Immunocytochemistry. After fixation and permeabilization, cells were incubated with primary antibodies and with corresponding Alexa dye-conjugated secondary antibodies (Molecular Probes, Eugene, OR, USA) and mounted onto microscope slides. For nuclear counterstaining, cells were incubated with TOPRO-3 (Molecular Probes). For g-H2AX and BrdU co-staining, cells were fixed and permeabilized. To denature DNA, fixed cells were resuspended in 4 N HCl and incubated for 30 min at 37 1C. After washing with borate buffer and phosphatebuffered saline (PBS) to remove any acid traces, cells were simultaneously incubated with a mouse anti-BrdU antibody and a rabbit anti-g-H2AX antibody. Primary antibodies were detected with a secondary Alexa 546-conjugated goat, anti-mouse antibody and a secondary Alexa 488-conjugated goat, anti-rabbit antibody. Images were obtained with either a Leica TCS SP5 laser-scanning confocal microscope (Leica, Wetzlar, Germany) or with a FluoView Olympus laser-scanning confocal microscope (Olympus, Tokyo, Japan). Images were transferred to Adobe Photoshop CS4 (Adobe Systems) for assembly.
Transmission electron microscopy. Immunolabeling was performed on formaldehyde-fixed and Lowicryl-K4M-embedded cells as described previously. 37 For ultrastructure, samples were washed in Sörensen's buffer and fixed for 1 h at 4 1C with 2.5% glutaraldehyde in Sörensen's 0.1 M phosphate buffer (pH 7.4), and post-fixed for 30 min with 1% osmium tetroxide. After dehydration in graded ethanol, samples were embedded in Epon. Ultrathin sections obtained with a Reichert Ultracut S ultramicrotome were contrasted with uranyl acetate and lead citrate. Observations were made with a Jeol 100 CX II transmission electron microscope at 60 kV.
MNaseI sensitivity assay. MCF-7 cells (1 Â 10 6 ) were Douncehomogenized in RSB buffer (10 mmol/l Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , 0.5% NP-40) containing 10 mg/ml aprotinin and leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , and 1 mM dithiothreitol (DTT), and incubated on ice for 15 min. Samples were centrifuged at 4 1C for 5 min at 1400 Â g, the medium was removed, samples were washed twice with RSB buffer, and digested with 0.25 to 2.5 U of micrococcal nuclease in digestion buffer (15 mM TrisHCl (pH 7.5), 60 mM KCl, 15 mM NaCl, 1 mM CaCl 2 , 3 mM MgCl 2 , 20% glycerol, 15 mM b-mercaptoethanol) for 5 min. Digestion was stopped by adding 1 volume of stop solution (50 mM Tris (pH 7.5), 150 mM NaCl, 50 mM EDTA, 0.3% sodium dodecyl sulfate (SDS)). DNA was extracted using 1 volume of phenol/chloroform/ isoamyl alcohol (25 : 24 : 1) followed by 1 volume chloroform/isoamyl alcohol (24 : 1) and precipitated with 100% ethanol. DNA was washed once with 70% ethanol, resuspended in H 2 O, and 1.5 mg of DNA was separated using 1.2% agarose gel.
Chromatin isolation. Chromatin fractionation was performed as described previously. 38 Three different fractions were collected: cytoplasmic fraction (S2), nuclear soluble proteins (S3), and chromatin-enriched fraction (P3).
Western blot analysis. Adherent (and floating depending on the experiment) cells were lysed into an SDS buffer (SDS 1%, Tris-HCl 40 mM (pH 7.5), EDTA 1 mM, protease inhibitor mixture) unless otherwise stated. Equal amounts of proteins were resolved by SDS-PAGE. Membranes were probed with primary antibodies, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies, and developed by chemiluminescence detection.
WST-1 cell viability. Cell survival was determined by WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) cell viability assay according to the manufacturer's instructions (Roche, Basel, Switzerland).
Cell-cycle analysis. The relative percentage of cells in each stage of the cell cycle was analyzed according to the procedure of labeling nuclei with propidium iodide (PI) followed by flow cytometric analysis using FACSCalibur II and the ModFit LT program.
In vitro DNA content measurement. Fluorimetric DNA titration was performed as described previously. 39 In vivo DNA replication assay. Cells were labeled with 33 mM BrdU for 30 min, resuspended in PBS þ 10% FBS, and then fixed with 70% cold ethanol. DNA was denatured with 4 N HCl þ 0.5% Triton X-100 for 30 min at 37 1C. After washing cells with PBS, the pellet was resuspended in PBS þ 10% FBS. An anti-BrdU antibody (clone BU-33; Sigma) was added and cells were incubated for 1 h at room temperature. After washing, an Alexa 488-conjugated goat, anti-mouse secondary antibody (Molecular Probes) was added for 1 h at room temperature in dark. After washing, cells were collected, resuspended in PI solution (EDTA 3 mM (pH 8.0), Tween 20 0.05%, PI 50 mg/ml, RNAse A 50 mg/ml in PBS), and analyzed using a FACSCalibur II and the CellQuest software (BD Biosciences).
DNA fiber assay. Cells were doubly labeled by incubating with 50 mM iododeoxyuridine (IdU) for 20 min followed by incubation with 50 mM chlorodeoxyuridine (CldU) for 30 min. A 2-ml volume of cells, resuspended in icecold PBS at 10 6 cells/ml, was spotted onto a silane-coated microscope slide (Sigma) and then overlaid with 10 ml of spreading buffer (SDS 0.5%, Tris-HCl 200 mM (pH 7.4), EDTA 50 mM). After 6 min, the slides were tilted by 15 degrees to allow lysates to slowly move down the slide. The DNA spreads were air-dried, fixed in a 3 : 1 mixture of methanol/acetic acid for 15 min at À20 1C, and stored in pre-chilled 70% ethanol at 4 1C overnight. The slides were then treated with 4 M HCl for 10 min at room temperature followed by 30 min at 37 1C in a water bath, washed three times in PBS, and incubated in blocking buffer (2% BSA in PBS) for 1 h at room temperature followed by 1 h at 37 1C with a rat anti-BrdU antibody (to detect CldU) (clone BU1/75; AbDSerotec) plus a mouse anti-BrdU (to detect IdU) (clone B44; BD Biosciences). After rinsing three times with stringency buffer (Tris-HCl 10 mM (pH 7.5), NaCl 400 mM, Tween 20 0.1%, NP-40 0.1%) the slides were incubated for 1 h with Alexa Fluor 488-conjugated rabbit, anti-mouse antibodies and Alexa Fluor 546-conjugated goat, anti-rat antibodies (Molecular Probes). Slides were rinsed three times with PBS, once with H 2 O, and mounted in Mowiol medium. Microscopy was performed using a FluoView Olympus laser-scanning confocal microscope using the sequential scanning mode. A single-blind evaluation was performed to measure the lengths of continuously double-stained tracks using the ImageJ software (NCI/NIH, Bethesda, MD, USA) and the collected images were processed using the Adobe Photoshop CS4 software (Adobe Systems). Pictures were taken on the entire slide and on multiple slides, reducing the chance of over-or underrepresenting certain origins or genomes of individual cells. Micrometer values were converted into kilobase using the conversion factor 1 mm ¼ 2.59 kb. Measurements were recorded from fibers in well-spread (untangled) areas of the slides to prevent the possibility of recording labeled patches from bundles of fibers.
Isolation of nascent-strand DNA. Isolation of nascent-strand DNA was performed as described previously. 40 The primers and PCR conditions are described by Rampakakis et al. 40 Annexin V staining. Apoptotic cells were determined by Annexin V-FITC (fluorescein isothiocyanate) and non-vital dye PI staining using an FITC-Annexin V apoptosis detection kit I (BD Biosciences) according to the manufacturer's instructions. Flow cytometry was performed using a FACSCanto and samples were analyzed using the CellQuest software (BD Biosciences). Both Annexin V þ /PI À cells representing early-apoptotic cells and Annexin V þ /PI þ mostly representing late-apoptotic/necrotic cells were considered as apoptotic cells.
CAM tumor model. A window was opened in the eggshell of a 3-day-old embryo using scissors after puncturing the air chamber. The window was sealed with tape and the eggs were incubated at 37 1C and 80% humidity until cell grafting. Eight days later, a Matrigel/cell mixture (1 : 1) was grafted within a plastic ring on the CAM surface. The window was sealed and eggs were incubated under the same conditions for 7 days. On day 18, tumors were dissected and diameters were measured with a caliper. Tumor volume was calculated using an ellipsoid formula: Volume (mm 3 ) ¼ (4 Â p Â Z 1 Â Z 2 Â Z 3 )/3, where Z 1À3 are the main radii of the tumor.
Statistical analyses. Results were reported as means with their S.D. or S.E.M. as reported in the figure legends. Statistical analysis was performed by one-way ANOVA or two-way ANOVA regarding the number of grouping factors. Group means were compared by Bonferroni's post-test. Homoscedasticity was assayed by Levene's test. Normality was assayed by the D'Agostino and Pearson test. All tests were performed with a 95% interval of confidence.
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